NVO
Novo Nordisk A/S
NVO offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
RVTY
Revvity, Inc.
RVTY has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RVTY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Stable |
RVTY's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over RVTY in the historical PE scenario, which offers more potential upside but is not a forecast.
RVTY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 18x | $40.50 | -74% |
| Forward | 27x | $157 | — |
| Fair | 37x | $84.05 | -46% |
| Expensive | 54x | $121 | -23% |
| Current | 70x | $157 | — |
Historical ranges are pointers, not guarantees.
RVTY's PE is in its expensive range at 70x. If earnings grow as analysts expect, today's price would be 27x next year's earnings, in its fair range.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RVTY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect RVTY's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over RVTY on earnings, with more consistent year-over-year improvement.
RVTY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.81 | +158% |
| Q3 2026 | $2.25 | +14% |
| Q2 2026 | $2.09 | -11% |
| Q1 2026 | $2.08 | -11% |
| Q4 2025 | $2.07 | -5.9% |
| Q3 2025 | $1.98 | -6.6% |
| Q2 2025 | $2.35 | +64% |
| Q1 2025 | $2.34 | +86% |
| Q4 2024 | $2.20 | -60% |
RVTY's earnings per share have fallen from their peak: $2.25 over the past year, against $10.51 in mid-2021.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RVTY on profitability, with a higher operating margin.
RVTY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $728.9M | +4.3% |
| Q2 2026 | $729.7M | +1.3% |
| Q1 2026 | $711.1M | +7% |
| Q4 2025 | $772.1M | +5.9% |
| Q3 2025 | $698.9M | +2.2% |
| Q2 2025 | $720.3M | +4.1% |
| Q1 2025 | $664.8M | +2.3% |
| Q4 2024 | $729.4M | +4.8% |
RVTY's revenue has grown year over year for nine quarters in a row: $729M last quarter, up 4.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | +1.3 points |
| Q2 2026 | 12% | -0.4 points |
| Q1 2026 | 11% | -0.2 points |
| Q4 2025 | 14% | -1.8 points |
| Q3 2025 | 12% | -2.6 points |
| Q2 2025 | 13% | +0.2 points |
| Q1 2025 | 11% | +4.1 points |
| Q4 2024 | 16% | +5.2 points |
RVTY's operating margin was 13% last quarter, up 1.3 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over RVTY on cash flow, with more consistent year-over-year improvement.
RVTY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $152.4M | +27% |
| Q2 2026 | $180.9M | +57% |
| Q1 2026 | $95.5M | -15% |
| Q4 2025 | $161.8M | +8% |
| Q3 2025 | $120M | -4.4% |
| Q2 2025 | $115.5M | -15% |
| Q1 2025 | $112.2M | -14% |
| Q4 2024 | $149.8M | -13% |
RVTY still generates free cash flow, though less than at its 2021 peak: $590M over the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RVTY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +197K shares |
| 1 year | -3.1% | -3.6M shares |
| 3 years | -10% | -12.4M shares |
| 5 years | -2.8% | -3.2M shares |
| Available history | +0.3% | +325K shares |
RVTY has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $95,000 |
| Q2 2026 | $16M |
| Q1 2026 | $86.5M |
| Q4 2025 | $168.3M |
| Q3 2025 | $205M |
| Q2 2025 | $293.9M |
| Q1 2025 | $153.6M |
| Q4 2024 | $185.2M |
RVTY spent $271M buying back its own shares over the past year, down 68% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over RVTY on leverage, with a lower net debt burden relative to earnings.
RVTY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.6x | Moderate |
| Q2 2026 | 2.8x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 3.0x | Elevated |
| Q3 2025 | 3.0x | Moderate |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.6x | Moderate |
RVTY's net debt is about 2.6 years of its operating earnings (EBITDA), down from 3.0 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RVTY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.3 | Overbought |
| Stochastic | 76.5 | Neutral |
RVTY's weekly RSI is 74 (overbought) and its Stochastic is 77 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over RVTY on valuation relative to its sector.
RVTY PE vs Healthcare Sector
| Metric | RVTY | Sector median | Relative |
|---|---|---|---|
| PE | 70x | 26x | 170% above |
| PE % | 91 | 29 | 62 pts above |
RVTY is trading at 70x earnings, a 170% premium to the Healthcare sector's median of 26x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RVTY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $154.7 | 1.5% above |
| 20 week MA | $134.0 | 17% above |
| 50 week MA | $112.2 | 40% above |
| 100 week MA | $105.9 | 48% above |
| 200 week MA | $110.0 | 43% above |
RVTY has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
RVTY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $97.1 | $139.7 | +44% |
| 2021 | $139.7 | $193.8 | +39% |
| 2022 | $193.8 | $140.6 | -27% |
| 2023 | $140.6 | $109.3 | -22% |
| 2024 | $109.3 | $112.0 | +2.5% |
| 2025 | $112.0 | $96.8 | -14% |
| 2026 YTD | $96.8 | $157.0 | +62% |
RVTY has the edge over NVO on returns for 2026, with the stronger performance.